We are excited to announce that SIGX1094, a potential therapy for diffuse gastric cancer, has received Orphan Drug Designation from the FDA. This marks a significant step in our mission to bring novel treatments to patients in need of effective therapies. #gastriccancer #noveltargettherapy #FDA
Signet Therapeutics Inc.
生物技术研究
Boston，Massachusetts 106 位关注者
Address Unmet Medical Needs Through Innovation.
关于我们
Signet Therapeutics is a preclinical stage biopharmaceutical company focusing on the development of first-in-class targeted cancer drugs based on disease models and AI. Driven by a vision to address highly unmet medical needs, we aim to improve the lives of cancer patients and bring them new hope. We came together as a team of experts who are dedicated to experimentation and driven by excellence. We push ourselves to work harder and remain fearless in our research and rigorous in our thinking. Join us: contact [email protected]
- 网站
-
www.signettx.com
Signet Therapeutics Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston，Massachusetts
- 类型
- 合营企业
- 创立
- 2020
地点
Signet Therapeutics Inc.员工
动态
-
We are thrilled to announce that SIGX1094 has received IND approval from both the FDA and NMPA ahead of schedule! This marks a significant step forward in bringing innovative and effective treatments to cancer patients, particularly for those with diffuse gastric cancer, where no therapies currently exist. We are now set to initiate multi-center clinical trials in both the U.S. and China. #biotech #innovation #organoid #diffusegastriccancer #addressunmetmedicalneeds
Signet Therapeutics' Targeted Therapy for Diffuse Gastric Cancer Receives IND Accelerated Approval by the NMPA
Signet Therapeutics Inc.，发布于领英
-
We are excited to announce the IND approval of sigx1094 by the FDA for world’s first targeted therapy for diffuse gastric cancer.
Signet Therapeutics Announces IND Approval by the FDA for World’s First Targeted Therapy for Diffuse Gastric Cancer
Signet Therapeutics Inc.，发布于领英